GRI Bio is a clinical stage biotech company focused on fundamentally changing the way inflammatory disease is treated by targeting NKT immune cells earlier in the inflammatory chain to interrupt disease progression more effectively. GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human Type 1 invariant NKT (iNKT) cells, returning the immune system to homeostasis. Oral...
GRI Bio is a clinical stage biotech company focused on fundamentally changing the way inflammatory disease is treated by targeting NKT immune cells earlier in the inflammatory chain to interrupt disease progression more effectively. GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human Type 1 invariant NKT (iNKT) cells, returning the immune system to homeostasis. Oral dosing of GRI-0621 has been shown to inhibit iNKT cells in patients and improve fibrosis in multiple disease models.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.